Exelixis (EXEL)
Develops and commercializes cancer medicines around cabozantinib and a broader oncology pipeline.
$57.66
vs last close−0.49 (−0.84%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≥ 95.83% | 237.44M shares | |
|---|---|---|---|
| 779 holders · as of Jun 30, 2026 · largest filers only | |||
| Insiders | 2.10% | 5.20M shares | |
| 15 holders · as of Aug 12, 2026 | |||
| Other | ≤ 2.07% | 5.14M shares | |
| remainder | |||
247.78M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the 99 largest filers, so at least this.
13F, as of Jun 30, 2026
779 holders · 237.44M shares · 133 new positions · 390 increased · 285 reduced · 77 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 29.08M | 11.73% | −1.74M | Aug 7, 2026 |
| Farallon Capital Management LLC | 13.47M | 5.44% | +357.0K | Aug 14, 2026 |
| Renaissance Technologies LLC | 13.43M | 5.42% | −299.0K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 12.04M | 4.86% | −42.2K | Aug 13, 2026 |
| AQR Capital Management LLC | 11.02M | 4.45% | −2.07M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 10.95M | 4.42% | −308.0K | Aug 13, 2026 |
| State Street Corp | 9.97M | 4.02% | −328.4K | Aug 7, 2026 |
| Fuller & Thaler Asset Management, Inc. | 8.93M | 3.60% | +387.2K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.20% | 28.50M | 13G | Apr 28, 2025 |
| Farallon Capital Management, L.L.C.incl. Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P. +26 more | 5.60% | 13.99M | 13D | Aug 14, 2026 |
| Vanguard Capital Management | 5.09% | 13.23M | 13G | Apr 29, 2026 |
| AQR Capital Management, LLC | 5.09% | 13.66M | 13G | Feb 13, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Mary C. Beckerledirector | Sale | 9,812 | $53.66 | 16,079 |
| Jun 1, 2026 | Sue Gail Eckhardtdirector | Sale | 9,812 | $50.14 | 16,079 |
| Jun 1, 2026 | Jack L. Wyszomierskidirector | Sale | 3,925 | $50.55 | 284,384 |
| May 26, 2026 | Dana Aftabofficer: EVP, Research and Development | Sale | 43,451 | $50.35 | 594,741 |
| May 20, 2026 | Patrick J. Haleyofficer: EVP, Commercial | Sale | 32,110 | $49.81 | 357,638 |
| May 18, 2026 | Brenda Heftiofficer: SVP and General Counsel | Sale | 6,625 | $50.21 | 106,762 |
| May 18, 2026 | Christopher J. Sennerofficer: EVP and CFO | Sale | 34,901 | $50.00 | 952,317 |
| May 7, 2026 | George Postedirector | Sale | 60,000 | $45.71 | 118,832 |
| May 7, 2026 | Maria C. Freiredirector | Sale | 20,634 | $46.00 | 100,819 |
| May 7, 2026 | Mary C. Beckerledirector | Sale | 7,712 | $48.45 | 17,524 |
House and Senate disclosures
Not reported.